Effect of Rosiglitazone on Hypertension induced by 5/6 Nephrectomy Rats

ObjectiveTo investigate the effects of rosiglitazone on BP in 5/6 nephrectomy rats, and explore the blood pressure regulating mechanism of rosiglitazone.MethodsChronic renal failure was induced by 5/6 nephrectomy, the nephrectomized rats were randomly allocated to rosiglitazone treatment group1 （5 mg/kg·d） （XL group） and triple dosage of rosiglitazone treatment group 2 （15 mg/kg·d） （DL group） for 8 wks, and control group（NX group）.The rats with sham operation served as control（SHAM group）.BUN, serum creatinine（SCr）, blood pressure（BP）, serum angiotensin Ⅱ（A 2）, endothelin（ET） were measured at the end of the study.ResultsCompared with the untreated 5/6 nephrectomized group （NX group）, SBP in rosiglitazone treatment group 1（5 mg/kg·d）, rosiglitazone treatment group 2 （15 mg/kg·d） rats were substantially decreased: SBP SHAM group: 126.7±8.5 vs NX:182.2±10.8 vs XL: 155.1±22.8 vs DL:148.3±12.0 mm Hg, which was confirmed by using common carotidarterial cannulation technique:SBP in SHAM group 146.0±11.6 vs NX group 202.9±13.0 vs XL group 182.8±5.7 vs DL group 166.1±1.8 mm Hg.DBP in SHAM:119.9±4.7 vs NX: 155.2±10.7 vs XL: 147.6±8.7 vs DL: 134.7±6.2 mm Hg （P＜0.01）.Serum angiotensin Ⅱ（Ang Ⅱ）:SHAM group 713.6±160.8 vs NX: 2022.2±487.7 vs XL: 1189.6±215.2 vs DL: 854.1±215.2 pg/mL, endothelin（ET）:SHAM: 192.6±45.3 vs NX: 360.9±80.3 vs XL: 279.7±34.4 vs DL: 204.8±32.7 pg/mL.ConclusionRosiglitazone obviously decreases BP in chronic renal failure rats is associated with decreases in plasma endothelin and angiotensin Ⅱ.